Defunct Company
Total Trials
9
As Lead Sponsor
As Collaborator
0
Total Enrollment
577
NCT04488601
Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study
Phase: Phase 2
Role: Lead Sponsor
Start: Jan 1, 2020
Completion: Dec 30, 2023
NCT04604704
Pilot Study Into LDN and NAD+ for Treatment of Patients With Post-COVID-19 Syndrome
Start: Jan 28, 2021
Completion: Jan 23, 2023
NCT04604678
Pilot Study Into the Use of Metformin and LDN for Patients With COVID-19
Start: Feb 28, 2021
Completion: Oct 31, 2021
NCT05307627
The Effects of Low Dose Naltrexone (LDN) on Diseases of Aging
Phase: N/A
Start: Mar 14, 2022
Completion: Dec 14, 2023
NCT05542849
The Efficacy and Tolerability of Acarbose in Healthy Individuals
Phase: Phase 4
Start: Aug 10, 2022
Completion: Oct 5, 2022
NCT06550271
The Bioavailability of Compounded and Generic Rapamycin in Normative Aging Individuals
Start: Apr 25, 2023
Completion: Dec 15, 2023
NCT06301529
The Efficacy and Tolerability of Canagliflozin in Healthy Individual
Start: Feb 12, 2024
Completion: Jun 29, 2024
NCT07092605
Effectiveness of Microdosed GLP-1 in Improving Health, Quality of Life, and Longevity Measures
Phase: Early Phase 1
Start: Nov 1, 2024
Completion: Dec 1, 2025
NCT07092618
Effectiveness of Alternative Therapies in Maintaining Weight Loss Achieved by GLP-1 Medications Post-Cessation
Phase: Phase 2/3
Start: Dec 17, 2024
Completion: Aug 31, 2025